Abstract

Simple SummaryProstate cancer is one of the leading causes of death among men worldwide. Advanced prostate cancer is an incurable disease whose mechanisms of action are still not fully understood. Secretion of the matrix protein MINDIN has been associated with prostate tumor development towards advanced prostate cancer. We aimed to study the mechanisms whereby MINDIN promotes prostate cancer progression. Evaluation of human and mouse prostate cancer samples showed increased MINDIN expression associated with decreased expression of the adaptor protein Na+/H+ exchanger regulatory factor 1 (NHERF-1). We found that NHERF-1 was downregulated by MINDIN in prostate cancer, causing an increase in tumor cell migration and proliferation. These observations point to NHERF-1 as a key modulator of MINDIN actions on prostate cancer progression and suggest that both proteins could be potential targets for the development of future prostate cancer therapies.Advanced prostate cancer preferential metastasis to bone is associated with osteomimicry. MINDIN is a secreted matrix protein upregulated in prostate tumors that overexpresses bone-related genes during prostate cancer progression. Na+/H+ exchanger regulatory factor (NHERF-1) is a scaffold protein that has been involved both in tumor regulation and osteogenesis. We hypothesize that NHERF-1 modulation is a mechanism used by MINDIN to promote prostate cancer progression. We analyzed the expression of NHERF-1 and MINDIN in human prostate samples and in a premetastatic prostate cancer mouse model, based on the implantation of prostate adenocarcinoma TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) cells in immunocompetent C57BL/6 mice. The relationship between NHERF-1 and MINDIN and their effects on cell proliferation, migration, survival and osteomimicry were evaluated. Upregulation of MINDIN and downregulation of NHERF-1 expression were observed both in human prostate cancer samples and in the TRAMP-C1 model. MINDIN silencing restored NHERF-1 expression to control levels in the mouse model. Stimulation with MINDIN reduced NHERF-1 expression and triggered its mobilization from the plasma membrane to the cytoplasm in TRAMP-C1 cells. MINDIN-dependent downregulation of NHERF-1 promoted tumor cell migration and proliferation without affecting osteomimicry and adhesion. We propose that MINDIN downregulates NHERF-1 expression leading to promotion of processes involved in prostate cancer progression.

Highlights

  • Prostate cancer is the second most common cancer among men after lung cancer and is one of the leading causes of cancer mortality and morbidity globally [1]

  • We have recently described that MINDIN is overexpressed in human prostate cancer cells associated with changes in osteomimicry markers [18], and regulates bone processes prior to metastatic development [19]

  • To test whether there is an association between MINDIN and the osteogenic-related factor Na+/H+ exchanger regulatory factor 1 (NHERF-1) in prostate cancer, we first analyzed by immunohistochemistry the expression and subcellular localization of MINDIN and NHERF-1 in human prostate control and tumor samples

Read more

Summary

Introduction

Prostate cancer is the second most common cancer among men after lung cancer and is one of the leading causes of cancer mortality and morbidity globally [1]. Cancer cells promote the secretion of growth factors and cytokines by osteoblasts (bone formation cells), osteoclasts (bone degradation or resorption cells) and osteocytes (bone monitoring cells). These factors, in turn, enhance tumor growth, metastatic cell proliferation and signaling [10,11]. The resulting “vicious cycle” of bone metastases changes bone physiology and triggers uncoupled bone remodeling [12,13,14] Since this process has not been characterized extensively, the study of factors that mediate prostate cancer bone metastasis could lead to the identification of potential diagnosis biomarkers or therapeutic targets

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call